Q2 2017 Holdings
Filed 2017-08-14 | 85 holdings | $88.5M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Biocryst Pharmaceuticals(BCRX) | COM | 09058V103 | $19.5M | 3,499,202 | 22.0% |
| Cytomx Therapeutics Inc(CTMX) | COM | 23284F105 | $11.7M | 756,822 | 13.3% |
| Ascendis Pharma A S(ASND) | SPONSORED ADR | 04351P101 | $11.6M | 419,453 | 13.2% |
| Ardelyx Inc(ARDX) | COM | 039697107 | $11.6M | 2,279,780 | 13.1% |
| Axogen Inc(AXGN) | COM | 05463X106 | $11.3M | 674,428 | 12.8% |
| Argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $10.8M | 509,022 | 12.2% |
| Aclaris Therapeutics Inc(ACRS) | COM | 00461U105 | $10.2M | 375,000 | 11.5% |
| Avexis Inc | COM | 05366U100 | $189.6K | 2,308,130 | 0.2% |
| Horizon Pharma PLC | SHS | G4617B105 | $106.8K | 8,998,413 | 0.1% |
| Nxstage Medical Inc | COM | 67072V103 | $96.1K | 3,833,330 | 0.1% |
| Gilead Sciences Inc(GILD) | COM | 375558103 | $66.4K | 938,515 | 0.1% |
| Horizon Pharma Invt LTD | NOTE 2.500% 3/1 | 44052TAB7 | $64.0K | $74,100,000 | 0.1% |
| Gilead Sciences Inc(GILD)Call | COM | 375558103 | $53.1K | 750,000 | 0.1% |
| Mylan N V | SHS EURO | N59465109 | $53.1K | 1,367,119 | 0.1% |
| Mallinckrodt PUB LTD Co | SHS | G5785G107 | $52.8K | 1,178,605 | 0.1% |
| Mckesson Corp(MCK) | COM | 58155Q103 | $51.9K | 315,417 | 0.1% |
| Aerie Pharmaceuticals Inc(AERIEUR) | COM | 00771V108 | $50.5K | 961,147 | 0.1% |
| Isis Pharmaceuticals Inc del | NOTE 1.000%11/1 | 464337AJ3 | $44.9K | $42,200,000 | 0.1% |
| Kempharm Inc | NOTE 5.500% 2/0 | 488445AB3 | $44.3K | $75,000,000 | 0.1% |
| Avadel Pharmaceuticals PLC | SPONSORED ADR | 05337M104 | $40.3K | 3,655,494 | 0.0% |
| Trinity Biotech Invt LTD | NOTE 4.000% 4/0 | 89643QAB4 | $38.4K | $48,000,000 | 0.0% |
| Glaukos Corp(GKOS) | COM | 377322102 | $37.1K | 894,551 | 0.0% |
| GW Pharmaceuticals PLC | ADS | 36197T103 | $36.1K | 359,983 | 0.0% |
| Endologix Inc | NOTE 3.250%11/0 | 29266SAB2 | $34.3K | $40,500,000 | 0.0% |
| Intersect ENT Inc | COM | 46071F103 | $33.2K | 1,189,577 | 0.0% |
| Audentes Therapeutics Inc(BOLDEUR) | COM | 05070R104 | $33.1K | 1,729,268 | 0.0% |
| Lannet Inc | COM | 516012101 | $31.1K | 1,523,957 | 0.0% |
| Nevro Corp | NOTE 1.750% 6/0 | 64157FAA1 | $29.6K | $27,600,000 | 0.0% |
| Editas Medicine Inc(EDIT) | COM | 28106W103 | $28.7K | 1,709,400 | 0.0% |
| Nevro Corp(NVROEUR) | COM | 64157F103 | $28.0K | 376,308 | 0.0% |
| DBV Technologies S A | SPONSORED ADR | 23306J101 | $23.8K | 665,197 | 0.0% |
| Portola Pharmaceuticals Inc | COM | 737010108 | $23.5K | 419,000 | 0.0% |
| Intercept Pharmaceuticals in | NOTE 3.250% 7/0 | 45845PAA6 | $22.0K | $22,500,000 | 0.0% |
| Selecta Biosciences Inc(SELBUSD) | COM | 816212104 | $21.1K | 1,060,000 | 0.0% |
| Syros Pharmaceuticals Inc | COM | 87184Q107 | $20.4K | 1,268,945 | 0.0% |
| Loxo Oncology Inc | COM | 548862101 | $20.1K | 251,167 | 0.0% |
| Aetna Inc New | COM | 00817Y108 | $19.7K | 130,000 | 0.0% |
| Patterson Companies Inc(PDCOEUR) | COM | 703395103 | $18.5K | 393,262 | 0.0% |
| Dexcom Inc(DXCM) | COM | 252131107 | $18.1K | 247,841 | 0.0% |
| Fluidigm Corp del | NOTE 2.750% 2/0 | 34385PAA6 | $17.2K | $27,715,000 | 0.0% |
| Oxford Immunotec Global PLC | ORD SHS | G6855A103 | $15.9K | 945,710 | 0.0% |
| Advanced Accelerator Applic | SPONSORED ADS | 00790T100 | $15.3K | 392,904 | 0.0% |
| Galapagos NV(GLPG) | SPON ADR | 36315X101 | $14.3K | 187,501 | 0.0% |
| Anthem Inc(ELV) | COM | 036752103 | $14.1K | 75,182 | 0.0% |
| Wave Life Sciences LTD(WVE) | SHS | Y95308105 | $13.9K | 746,841 | 0.0% |
| AAC Hldgs Inc(AACH) | COM | 000307108 | $13.7K | 1,975,347 | 0.0% |
| Aegerion Pharmaceuticals Inc | NOTE 2.000% 8/1 | 00767EAB8 | $13.5K | $16,600,000 | 0.0% |
| Recro Pharma Inc | COM | 75629F109 | $13.4K | 1,901,685 | 0.0% |
| Anaptysbio Inc(ANAB) | COM | 032724106 | $13.2K | 552,859 | 0.0% |
| Ehealth Inc(EHTH) | COM | 28238P109 | $13.0K | 690,348 | 0.0% |